Stockscreener 앱 받기
1,017.97
3.23%
-34.02
시장 영업 전:
1007.68
-10.29
-1.01%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave - The Economic Times
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Laurel Wealth Advisors LLC Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Finemark National Bank & Trust Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Artisan Partners Limited Partnership Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Ibex Wealth Advisors Sells 5,897 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat
Eli Lilly and Company $LLY Position Boosted by Clal Insurance Enterprises Holdings Ltd - MarketBeat
American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Trading Up 2.8% Following Analyst Upgrade - MarketBeat
Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable (NYSE:NVO) - Seeking Alpha
Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle - Fierce Biotech
The New Magnificent Stocks to Own in 2026 - Investing.com
Eli Lilly launches LillyPod, pharma's most powerful supercomputer - R&D World
Is the Market Bullish or Bearish on Eli Lilly and Co? - Benzinga
Lilly’s Olumiant receives positive EU opinion for adolescent alopecia - Investing.com
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Eli Lilly and Company $LLY Position Decreased by MGB Wealth Management LLC - MarketBeat
Handelsbanken Fonder AB Purchases 92,689 Shares of Eli Lilly and Company $LLY - MarketBeat
Generali Investments Management Co LLC Acquires 3,281 Shares of Eli Lilly and Company $LLY - MarketBeat
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Eli Lilly and Company $LLY Shares Sold by FUKOKU MUTUAL LIFE INSURANCE Co - MarketBeat
Lilly unveils supercomputer to expand AI drug discovery push - The Pharma Letter
Close Asset Management Ltd Has $43.54 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly, Nvidia Launch LillyPod: Pharma’s First ‘AI Factory’ in Indianapolis - TipRanks
Navigating Price Competition: Eli Lilly's Strategic Position in the Weight-Loss Drug Market - AD HOC NEWS
1ST Source Bank Sells 983 Shares of Eli Lilly and Company $LLY - MarketBeat
RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market - Finviz
Lilly’s Orforglipron Tops Novo’s Semaglutide In Diabetes Trial - Citeline News & Insights
Friday Five – Novo's no-go week, tolerability tempers Lilly's oral edge, GSK makes pulmonary hypertension play…and more - FirstWord Pharma
Now Live: The World’s Most Powerful AI Factory for Pharmaceutical Discovery and Development - NVIDIA Blog
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 - Benzinga
Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet - Investing News Network
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Latest Research: Eli Lilly and Co's Oral Weight-Loss Drug Orforglipron Demonstrates Superior Weight Loss Effects Compared to Semaglutide Tablets - 富途牛牛
Building permit issued for $77M expansion at Eli Lilly manufacturing campus in Concord - The Business Journals
Eli Lilly and Company GLP-1 pill outperforms rival in type 2 diabetes trial - Traders Union
Eli Lilly's weight-loss pill shows higher side effects than Novo rival in diabetes trial - Reuters
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly Shares Weather Competitive Pricing Move - AD HOC NEWS
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy HQ - Inside INdiana Business
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indianapolis Business Journal
Eli Lilly Prevails in Appeal of Licensor’s Drug Royalty Claim - Bloomberg Law News
9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case - Law360
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics - The Chronicle-Journal
Eli Lilly Strengthens Market Leadership as Rival Stumbles - AD HOC NEWS
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - aol.com
Assessing Eli Lilly: Insights From 13 Financial Analysts - Benzinga
Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market - thestreet.com
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study - Finviz
Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact - Finviz
Novo Nordisk's Loss Is Eli Lilly's Gain - AOL.com
Bernstein reiterates Eli Lilly stock rating after Novo pricing move By Investing.com - Investing.com Canada
Ozempic Price War - Benzinga
Thoroughbred Financial Services LLC Sells 4,901 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly stock price forecast: Steadies around $1,042 after recent pullback - Traders Union
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,300 - 富途牛牛
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Benzinga
Eli Lilly Strengthens Lead in Weight-Loss Drug Market with New Clinical Data - AD HOC NEWS
Eli Lilly Strengthens Market Lead with Clinical and Commercial Wins - AD HOC NEWS
Intensifying Price War in Weight-Loss Drugs Hits Eli Lilly Stock - Intellectia AI
0.05%
1.04%
자본화:
|
볼륨(24시간):